Martin Pharmaceuticals, a clinical stage pharmaceutical company focused on repurposing already-approved drugs to offer life-changing advances to patients afflicted with rare (orphan) diseases or challenging medical conditions, has been granted Orphan Drug Designation by the FDA for Livantra in the treatment of Pulmonary Arterial Hypertension. Earlier this year Livantra received orphan drug designation for the treatment…
Martin Pharmaceuticals Receives FDA Orphan Drug Designation For Livantra
Martin Pharmaceuticals, a clinical stage pharmaceutical company focused on repurposing already-approved drugs to offer life-changing advances to patients afflicted with rare (orphan) diseases or challenging medical conditions, has been granted Orphan Drug Designation by the FDA for Livantra in the treatment of Acute on Chronic Liver Failure. Orphan drug designation is granted to novel drugs…